1980
DOI: 10.1016/0002-9343(80)90181-3
|View full text |Cite
|
Sign up to set email alerts
|

Maternal and fetal sequelae of anticoagulation during pregnancy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

9
411
2
21

Year Published

1986
1986
2007
2007

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 944 publications
(443 citation statements)
references
References 96 publications
9
411
2
21
Order By: Relevance
“…Hence, vitamin K is an important regulator of bone and cartilage mineralization. Vitamin K also regulates growth plate cartilage calcification, as revealed by effects of vitamin K antagonism by warfarin (6)(7)(8)(9)(10). Genetic deficiencies of MGP in humans and mice have been linked to skeletal abnormalities, including premature epiphyseal calcification and shortening of long limb bones, reflecting endochondral bone formation (11)(12)(13)(14).…”
mentioning
confidence: 99%
“…Hence, vitamin K is an important regulator of bone and cartilage mineralization. Vitamin K also regulates growth plate cartilage calcification, as revealed by effects of vitamin K antagonism by warfarin (6)(7)(8)(9)(10). Genetic deficiencies of MGP in humans and mice have been linked to skeletal abnormalities, including premature epiphyseal calcification and shortening of long limb bones, reflecting endochondral bone formation (11)(12)(13)(14).…”
mentioning
confidence: 99%
“…Circulating levels of vita min K in osteoporotic patients have been shown to be significantly lower than those in age-matched control subjects (2). The use of a coumarin-related vitamin K an tagonist during pregnancy was found to cause character istic nasal hypoplasia or stippled epiphysis (3). A vitamin K2 homologue, menatetrenone (MK-4), was shown to be effective in ameliorating bone loss induced by ovari ectomy in rats (4), and the clinical efficacy of MK-4 was demonstrated in a double-blind multi-center comparative study with alfacalcidol in patients with postmenopausal and senile osteoporosis (5).…”
mentioning
confidence: 99%
“…[6][7][8][9] There are no reliable data about the incidence of warfarin embryopathy (5 to 67%), but the risk is diminished when a maximum of 5 mg warfarin is given daily. [5][6][7][8]10 In contrast to warfarin, both unfractionated and low-molecular-weight heparin (LMWH) do not cross the placenta, because of the larger molecular structure 11 and as a consequence decrease the risk of embryopathy. 5 However, the use of LMWH in prosthetic valve patients is not approved, because a recent survey was ended after a high incidence of PHV thrombosis.…”
Section: A B a Bmentioning
confidence: 99%
“…Recent recommendations advocate substituting warfarin after 35 weeks, because of the risk for intracranial haemorrhage of the child during delivery. 8,14 If there is no major bleeding after delivery, unfractionated heparin needs to be restarted four to six hours after delivery and oral anticoagulation can be given after 24 hours (target INR 2.5 to 3.5 in high-risk patients and 2.0 to 3.0 in low-risk patients.…”
Section: A B a Bmentioning
confidence: 99%